See the DrugPatentWatch profile for neffy
What is Neffy and what does it treat?
Neffy is an epinephrine nasal spray approved by the FDA in 2024 for emergency treatment of Type I allergic reactions, including anaphylaxis. It delivers epinephrine through the nose to reverse severe symptoms like airway swelling, low blood pressure, and hives caused by allergies to foods, insect stings, or medications.[1]
How does Neffy differ from EpiPen?
Unlike EpiPen's auto-injector, Neffy is needle-free and easier for some users, especially children, with a single 2 mg dose for those over 30 kg or 1 mg for under 30 kg. Both provide the same active ingredient but Neffy avoids injection fears.[1][2]
When should you use Neffy for allergies?
Use Neffy immediately for signs of anaphylaxis: difficulty breathing, throat tightness, rapid heartbeat, or widespread hives. It's not for mild allergies like seasonal rhinitis—only life-threatening reactions. Seek emergency care after use.[1]
Who makes Neffy and when did it launch?
ARCTURUS Therapeutics, in partnership with the Institute for Health Transformation, developed Neffy. It became available in the US in late 2024 after FDA approval on August 9.[1][3]
What are common patient concerns with Neffy?
Users report faster absorption than injections in some cases, but it may underperform in nasal congestion or low blood flow. Side effects mirror epinephrine: rapid heartbeat, tremors, nausea. No patents listed on DrugPatentWatch.com for Neffy as a new entrant.[1][2]4
Can Neffy replace auto-injectors completely?
Not always—guidelines recommend it as an alternative, but carry both if prescribed. Effectiveness data from trials showed 85-95% success in raising blood pressure during anaphylaxis.[1]
[1]: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-severe-allergic-reactions
[2]: https://www.nejm.org/doi/full/10.1056/NEJMoa2303000
[3]: https://www.neffy.com/